Category : Search result: Purdue Pharma bankruptcy

Real Estate Bankruptcy Reforms Delayed, Separate from Upcoming IBC Amendments

Realty IBC Reforms Pushed to Later Phase

Government to introduce corporate IBC amendments first, delaying structural reforms for homebuyers and stuck projects. Key changes for real estate require further consultation. #IBC #RealEstate

Anupam Kher's Bankruptcy Journey: From Rs 400 to Rs 3 Crore Per Film

Anupam Kher: From Rs 400 to Rs 3 Crore Per Film

Anupam Kher reveals how he faced near bankruptcy with only Rs 400 in bank, mortgaged properties, and made remarkable comeback charging Rs 3 crore per film. Read his inspiring story.

Jaiprakash Gaur's Empire Crumbles Under ₹57,000 Crore Debt

Jaiprakash Gaur's Legacy Ends in Bankruptcy

At 94, Jaiprakash Gaur watches his life's work collapse as NCLT admits Jaiprakash Associates into insolvency. Read about his rags-to-riches story and ultimate downfall.

Sudeep Pharma IPO Lists Today: 20% Gains Expected After 93x Subscription

Sudeep Pharma IPO Lists on BSE, NSE Today

Sudeep Pharma makes its stock market debut today. With a GMP of ₹121, the IPO is set for 20% listing gains after a blockbuster 93.72 times subscription. Get all the live details.

India's IBC Set for Major Reforms in December Parliament Session

IBC Reforms: Biggest Changes in 9 Years Coming

India's Insolvency and Bankruptcy Code undergoes major reforms with cross-border insolvency and faster debt resolution. Parliament to consider revised bill in December session.

Sudeep Pharma IPO Subscribed 94x as Institutional Demand Soars

Sudeep Pharma IPO Subscribed 94 Times

Sudeep Pharma's ₹895 crore IPO witnessed massive demand, subscribed 94 times. QIB portion booked 213x. Shares may list at a 14% premium. Key details inside.

Lupin at 21x P/E: Undervalued Pharma Giant Ready for Growth Cycle?

Lupin: Undervalued Pharma Giant at 21x P/E?

Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.

Sudeep Pharma IPO Fully Subscribed on Day 1, Grey Market Signals Strong Debut

Sudeep Pharma IPO Fully Subscribed on Day 1

Sudeep Pharma's IPO concludes November 25 after strong第一天 response. Grey market premium hits ₹121, signaling 20% listing gains. Key dates and subscription details revealed.

10 Key Bills in Winter Session: Nuclear Energy, Higher Education Reform

10 Bills for Parliament Winter Session 2025

Indian government lists 10 crucial bills for Winter Session including Atomic Energy Bill 2025 and Higher Education Commission Bill. Key reforms in nuclear sector, education, and economy await parliamentary approval.

IBBI Proposes New Valuation Format to Reduce Bankruptcy Litigation

IBBI's New Valuation Format Aims to Cut Litigation

IBBI introduces standardized valuation format for distressed assets to enhance transparency and reduce lawsuits. Public feedback accepted until December 10. Learn how this impacts creditors.

Sudeep Pharma IPO Opens Nov 21: 22% GMP Premium, Key Details

Sudeep Pharma IPO: 22% GMP, Opens Nov 21

Sudeep Pharma's ₹95 crore IPO opens November 21 with strong grey market premium. Learn price band, dates, financials & investment details for this pharma ingredients maker.

Adani Wins Bid for Jaiprakash Associates With ₹14,500 Cr Resolution Plan

Adani Wins Bid for Bankrupt Jaiprakash Associates

Gautam Adani's Adani Enterprises secures creditors' approval to take over bankrupt Jaiprakash Associates, gaining assets worth ₹35,000 crore across cement, power and hospitality sectors.

Adani Wins $1.53 Billion Jaiprakash Takeover with Creditor Approval

Adani wins $1.53bn Jaiprakash takeover bid

Adani Enterprises secures creditor approval for $1.53 billion Jaiprakash Associates acquisition, beating Vedanta's higher offer with better payment terms. Key details inside.

Page 2 of 4